Compare BGDE & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BGDE | GRML |
|---|---|---|
| Founded | N/A | N/A |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 29.2M |
| IPO Year | 2013 | 2022 |
| Metric | BGDE | GRML |
|---|---|---|
| Price | $6.87 | $4.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 58.7K | ★ 5.9M |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,754,085.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.58 | $0.16 |
| 52 Week High | $11.69 | $11.66 |
| Indicator | BGDE | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 60.60 |
| Support Level | $5.81 | $0.20 |
| Resistance Level | $6.57 | $11.66 |
| Average True Range (ATR) | 0.58 | 0.60 |
| MACD | -0.05 | 0.15 |
| Stochastic Oscillator | 14.21 | 39.44 |
Big Digital Energy Inc, formerly Mawson Infrastructure Group Inc is focused on digital infrastructure platforms. It designs, builds and operates next-generation digital infrastructure platforms for enterprise customers and for its own purposes. The company provides services spanning AI, HPC, digital assets including Bitcoin mining, and other intensive compute applications. The company delivers both self-mining operations and colocation services to enterprise customers with a vertically integrated infrastructure model built for scalability and efficiency. The company also has an energy management business, which utilizes software and analysis, to generate revenue by participating in energy management programs. It operates as one energy management and digital asset mining segment.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.